Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Typhoid Fever | 44 | 2023 | 46 | 12.700 |
Why?
|
Disease Outbreaks | 52 | 2023 | 155 | 10.260 |
Why?
|
Cholera | 40 | 2023 | 70 | 9.880 |
Why?
|
Diarrhea | 47 | 2023 | 89 | 7.560 |
Why?
|
Salmonella typhi | 31 | 2023 | 33 | 6.920 |
Why?
|
Sanitation | 20 | 2023 | 26 | 4.210 |
Why?
|
Water Supply | 23 | 2023 | 57 | 3.620 |
Why?
|
Typhoid-Paratyphoid Vaccines | 11 | 2020 | 11 | 3.260 |
Why?
|
Child, Preschool | 76 | 2023 | 1418 | 3.030 |
Why?
|
Anti-Bacterial Agents | 26 | 2023 | 352 | 2.600 |
Why?
|
Travel | 15 | 2021 | 32 | 2.590 |
Why?
|
Infant | 61 | 2023 | 1046 | 2.420 |
Why?
|
Feces | 24 | 2023 | 111 | 2.240 |
Why?
|
Cholera Vaccines | 10 | 2023 | 18 | 2.050 |
Why?
|
Water Purification | 10 | 2020 | 28 | 2.020 |
Why?
|
Salmonella Infections | 7 | 2021 | 17 | 1.840 |
Why?
|
Child | 59 | 2023 | 3131 | 1.840 |
Why?
|
Dysentery, Bacillary | 11 | 2015 | 13 | 1.820 |
Why?
|
Humans | 158 | 2023 | 37093 | 1.810 |
Why?
|
Vibrio cholerae O1 | 6 | 2018 | 11 | 1.780 |
Why?
|
Case-Control Studies | 36 | 2023 | 1130 | 1.630 |
Why?
|
Paratyphoid Fever | 7 | 2018 | 7 | 1.600 |
Why?
|
Water Microbiology | 14 | 2020 | 76 | 1.520 |
Why?
|
Kenya | 29 | 2023 | 50 | 1.470 |
Why?
|
Hygiene | 8 | 2020 | 14 | 1.460 |
Why?
|
Drug Resistance, Bacterial | 9 | 2016 | 77 | 1.410 |
Why?
|
Population Surveillance | 17 | 2018 | 238 | 1.340 |
Why?
|
Escherichia coli Infections | 8 | 2023 | 41 | 1.340 |
Why?
|
Endemic Diseases | 3 | 2016 | 20 | 1.330 |
Why?
|
Female | 85 | 2023 | 20969 | 1.300 |
Why?
|
Vaccination | 7 | 2015 | 288 | 1.270 |
Why?
|
Male | 83 | 2023 | 20025 | 1.240 |
Why?
|
Adolescent | 51 | 2020 | 5363 | 1.230 |
Why?
|
Adult | 63 | 2021 | 11712 | 1.150 |
Why?
|
Middle Aged | 53 | 2020 | 10129 | 1.040 |
Why?
|
Young Adult | 33 | 2020 | 4268 | 0.990 |
Why?
|
Drug Resistance, Multiple, Bacterial | 7 | 2020 | 30 | 0.960 |
Why?
|
Cryptosporidiosis | 6 | 2023 | 6 | 0.950 |
Why?
|
Ceftriaxone | 2 | 2021 | 7 | 0.940 |
Why?
|
Fever | 4 | 2021 | 57 | 0.930 |
Why?
|
Salmonella | 2 | 2021 | 11 | 0.930 |
Why?
|
Microbial Sensitivity Tests | 16 | 2022 | 201 | 0.920 |
Why?
|
Risk Factors | 28 | 2023 | 3562 | 0.910 |
Why?
|
Aged, 80 and over | 22 | 2020 | 2379 | 0.910 |
Why?
|
Aged | 36 | 2020 | 6741 | 0.910 |
Why?
|
Incidence | 21 | 2023 | 922 | 0.900 |
Why?
|
Family Characteristics | 8 | 2018 | 108 | 0.870 |
Why?
|
Infant, Newborn | 23 | 2023 | 894 | 0.870 |
Why?
|
Food Microbiology | 11 | 2020 | 34 | 0.860 |
Why?
|
Rural Population | 13 | 2018 | 294 | 0.840 |
Why?
|
Shigella | 6 | 2021 | 10 | 0.840 |
Why?
|
Foodborne Diseases | 6 | 2014 | 22 | 0.830 |
Why?
|
United States | 27 | 2021 | 4223 | 0.790 |
Why?
|
Drug Resistance, Microbial | 2 | 2020 | 26 | 0.770 |
Why?
|
Haiti | 13 | 2017 | 68 | 0.770 |
Why?
|
Escherichia coli | 11 | 2021 | 453 | 0.740 |
Why?
|
Sepsis | 1 | 2021 | 80 | 0.730 |
Why?
|
Rotavirus Infections | 6 | 2023 | 15 | 0.700 |
Why?
|
Uganda | 7 | 2021 | 22 | 0.660 |
Why?
|
Communicable Disease Control | 3 | 2013 | 32 | 0.650 |
Why?
|
Funeral Rites | 1 | 2018 | 1 | 0.640 |
Why?
|
Cryptosporidium | 4 | 2023 | 4 | 0.630 |
Why?
|
Financing, Personal | 1 | 2017 | 9 | 0.620 |
Why?
|
Vibrio cholerae | 7 | 2018 | 98 | 0.620 |
Why?
|
Health Expenditures | 1 | 2017 | 32 | 0.600 |
Why?
|
Electrophoresis, Gel, Pulsed-Field | 9 | 2014 | 27 | 0.600 |
Why?
|
Disinfection | 3 | 2007 | 9 | 0.570 |
Why?
|
Disease Transmission, Infectious | 3 | 2013 | 29 | 0.570 |
Why?
|
Enteritis | 1 | 2016 | 4 | 0.550 |
Why?
|
Cholera Toxin | 2 | 2008 | 39 | 0.550 |
Why?
|
Cost of Illness | 6 | 2016 | 76 | 0.540 |
Why?
|
Time Factors | 12 | 2020 | 1742 | 0.530 |
Why?
|
Africa | 9 | 2019 | 76 | 0.530 |
Why?
|
World Health Organization | 7 | 2015 | 31 | 0.520 |
Why?
|
Urban Health | 1 | 2016 | 95 | 0.520 |
Why?
|
Developing Countries | 9 | 2019 | 99 | 0.520 |
Why?
|
Shigella flexneri | 4 | 2015 | 6 | 0.510 |
Why?
|
Delivery of Health Care | 1 | 2017 | 276 | 0.500 |
Why?
|
Malawi | 4 | 2018 | 9 | 0.500 |
Why?
|
Laboratories | 4 | 2022 | 35 | 0.500 |
Why?
|
Topography, Medical | 1 | 2014 | 2 | 0.480 |
Why?
|
Logistic Models | 10 | 2020 | 923 | 0.470 |
Why?
|
Infectious Disease Transmission, Patient-to-Professional | 1 | 2013 | 6 | 0.470 |
Why?
|
Africa South of the Sahara | 10 | 2019 | 46 | 0.470 |
Why?
|
Cluster Analysis | 5 | 2019 | 195 | 0.470 |
Why?
|
Food Contamination | 4 | 2017 | 55 | 0.460 |
Why?
|
Pakistan | 3 | 2022 | 20 | 0.450 |
Why?
|
Shigella sonnei | 4 | 2009 | 5 | 0.450 |
Why?
|
Hospitalization | 6 | 2016 | 388 | 0.430 |
Why?
|
Nervous System | 1 | 2012 | 29 | 0.430 |
Why?
|
Child Mortality | 1 | 2012 | 7 | 0.430 |
Why?
|
Disasters | 4 | 2014 | 65 | 0.420 |
Why?
|
Doxycycline | 1 | 2012 | 30 | 0.420 |
Why?
|
Leptospira | 1 | 2012 | 22 | 0.420 |
Why?
|
Intestinal Perforation | 1 | 2012 | 10 | 0.420 |
Why?
|
Vaccines | 2 | 2023 | 55 | 0.420 |
Why?
|
Leptospirosis | 1 | 2012 | 25 | 0.410 |
Why?
|
Immunization Programs | 4 | 2017 | 24 | 0.410 |
Why?
|
Sensitivity and Specificity | 8 | 2015 | 562 | 0.410 |
Why?
|
Zimbabwe | 4 | 2019 | 5 | 0.400 |
Why?
|
Halogenation | 1 | 2011 | 19 | 0.390 |
Why?
|
Nervous System Diseases | 1 | 2012 | 71 | 0.390 |
Why?
|
Health Personnel | 1 | 2013 | 228 | 0.390 |
Why?
|
Bacteremia | 4 | 2019 | 30 | 0.380 |
Why?
|
Fishes | 1 | 2011 | 53 | 0.380 |
Why?
|
Diagnostic Tests, Routine | 3 | 2015 | 47 | 0.370 |
Why?
|
Odds Ratio | 11 | 2020 | 534 | 0.370 |
Why?
|
Fluid Therapy | 6 | 2013 | 28 | 0.370 |
Why?
|
Anti-Infective Agents | 3 | 2012 | 64 | 0.360 |
Why?
|
Soaps | 3 | 2020 | 3 | 0.360 |
Why?
|
Chlorine | 6 | 2020 | 8 | 0.360 |
Why?
|
Severity of Illness Index | 5 | 2021 | 610 | 0.350 |
Why?
|
Health Knowledge, Attitudes, Practice | 6 | 2018 | 864 | 0.350 |
Why?
|
Norovirus | 5 | 2023 | 10 | 0.340 |
Why?
|
Vibrio cholerae non-O1 | 1 | 2008 | 2 | 0.330 |
Why?
|
Ciprofloxacin | 4 | 2023 | 14 | 0.310 |
Why?
|
Rotavirus | 4 | 2023 | 11 | 0.310 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 404 | 0.300 |
Why?
|
Shigella dysenteriae | 1 | 2007 | 1 | 0.300 |
Why?
|
Shiga Toxin 1 | 1 | 2007 | 3 | 0.300 |
Why?
|
Restaurants | 6 | 2008 | 39 | 0.300 |
Why?
|
Urban Population | 5 | 2020 | 333 | 0.300 |
Why?
|
Age Distribution | 5 | 2013 | 225 | 0.290 |
Why?
|
Salmonella paratyphi A | 4 | 2018 | 4 | 0.280 |
Why?
|
Equipment Contamination | 1 | 2006 | 5 | 0.280 |
Why?
|
Asia | 5 | 2019 | 75 | 0.280 |
Why?
|
Disaster Planning | 1 | 2007 | 52 | 0.280 |
Why?
|
Serotyping | 6 | 2014 | 36 | 0.270 |
Why?
|
Metals | 1 | 2006 | 98 | 0.260 |
Why?
|
Diarrhea, Infantile | 3 | 2013 | 5 | 0.250 |
Why?
|
Cattle | 2 | 2023 | 477 | 0.250 |
Why?
|
Dysentery | 2 | 2019 | 2 | 0.250 |
Why?
|
Clinical Competence | 1 | 2006 | 130 | 0.250 |
Why?
|
Enterotoxigenic Escherichia coli | 2 | 2019 | 5 | 0.250 |
Why?
|
Sentinel Surveillance | 2 | 2015 | 21 | 0.250 |
Why?
|
Rotavirus Vaccines | 2 | 2023 | 12 | 0.250 |
Why?
|
Fresh Water | 1 | 2004 | 48 | 0.240 |
Why?
|
Serologic Tests | 1 | 2004 | 43 | 0.230 |
Why?
|
Administration, Oral | 4 | 2017 | 224 | 0.230 |
Why?
|
Animals | 14 | 2023 | 15081 | 0.230 |
Why?
|
HIV Infections | 6 | 2018 | 2303 | 0.230 |
Why?
|
Health Education | 4 | 2020 | 338 | 0.230 |
Why?
|
Enteropathogenic Escherichia coli | 1 | 2023 | 3 | 0.230 |
Why?
|
Ethiopia | 1 | 2023 | 9 | 0.230 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2023 | 5 | 0.230 |
Why?
|
Shellfish | 2 | 2014 | 13 | 0.220 |
Why?
|
Bacteria | 1 | 2006 | 255 | 0.220 |
Why?
|
Quinolones | 1 | 2022 | 7 | 0.220 |
Why?
|
Mozambique | 2 | 2012 | 3 | 0.220 |
Why?
|
Enterobacteriaceae | 3 | 2013 | 28 | 0.210 |
Why?
|
Growth Disorders | 1 | 2021 | 22 | 0.200 |
Why?
|
Salmonella enterica | 3 | 2015 | 9 | 0.200 |
Why?
|
Gastroenteritis | 3 | 2007 | 17 | 0.200 |
Why?
|
Child, Hospitalized | 1 | 2021 | 1 | 0.200 |
Why?
|
Sexually Transmitted Diseases | 1 | 2003 | 164 | 0.200 |
Why?
|
Public Health | 5 | 2018 | 372 | 0.190 |
Why?
|
Bacterial Infections | 3 | 2013 | 43 | 0.190 |
Why?
|
Guinea-Bissau | 2 | 2011 | 2 | 0.190 |
Why?
|
Iraq | 1 | 2020 | 7 | 0.190 |
Why?
|
Polymerase Chain Reaction | 5 | 2019 | 448 | 0.180 |
Why?
|
Zambia | 4 | 2020 | 40 | 0.180 |
Why?
|
Communicable Diseases | 2 | 2018 | 45 | 0.180 |
Why?
|
Prevalence | 7 | 2019 | 1455 | 0.180 |
Why?
|
Glass | 2 | 2009 | 15 | 0.180 |
Why?
|
Filtration | 2 | 2018 | 14 | 0.180 |
Why?
|
Dominican Republic | 2 | 2011 | 20 | 0.180 |
Why?
|
Carrier State | 1 | 2019 | 29 | 0.170 |
Why?
|
Thrombectomy | 1 | 2019 | 13 | 0.170 |
Why?
|
Antibodies, Bacterial | 3 | 2012 | 109 | 0.170 |
Why?
|
Cost-Benefit Analysis | 3 | 2015 | 144 | 0.170 |
Why?
|
Silver | 2 | 2009 | 54 | 0.170 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 2009 | 41 | 0.170 |
Why?
|
Fimbriae Proteins | 1 | 2019 | 21 | 0.170 |
Why?
|
Health Services Research | 1 | 2019 | 148 | 0.160 |
Why?
|
DNA, Bacterial | 3 | 2008 | 186 | 0.160 |
Why?
|
Ceramics | 1 | 2018 | 4 | 0.160 |
Why?
|
Predictive Value of Tests | 3 | 2009 | 400 | 0.160 |
Why?
|
Security Measures | 1 | 2018 | 5 | 0.160 |
Why?
|
Prospective Studies | 6 | 2019 | 1378 | 0.160 |
Why?
|
Virulence Factors | 1 | 2019 | 113 | 0.150 |
Why?
|
Animals, Domestic | 1 | 2017 | 8 | 0.150 |
Why?
|
Toilet Facilities | 1 | 2017 | 2 | 0.150 |
Why?
|
Government Programs | 1 | 2017 | 29 | 0.150 |
Why?
|
Homosexuality, Male | 1 | 2003 | 458 | 0.150 |
Why?
|
Costs and Cost Analysis | 1 | 2017 | 57 | 0.150 |
Why?
|
Multivariate Analysis | 3 | 2017 | 583 | 0.150 |
Why?
|
Refugees | 1 | 2017 | 19 | 0.150 |
Why?
|
Gram-Negative Bacterial Infections | 3 | 2009 | 22 | 0.150 |
Why?
|
Capacity Building | 1 | 2018 | 87 | 0.140 |
Why?
|
Metal Nanoparticles | 2 | 2009 | 183 | 0.140 |
Why?
|
Perception | 2 | 2017 | 195 | 0.140 |
Why?
|
Poverty | 1 | 2019 | 348 | 0.140 |
Why?
|
Quality of Health Care | 1 | 2017 | 138 | 0.140 |
Why?
|
Blood | 2 | 2014 | 37 | 0.140 |
Why?
|
Agglutination Tests | 2 | 2014 | 5 | 0.140 |
Why?
|
Food Handling | 3 | 2012 | 33 | 0.140 |
Why?
|
Clinical Laboratory Techniques | 2 | 2015 | 26 | 0.140 |
Why?
|
Immunoassay | 2 | 2016 | 61 | 0.140 |
Why?
|
Seasons | 1 | 2016 | 112 | 0.140 |
Why?
|
Polysaccharides, Bacterial | 2 | 2014 | 12 | 0.140 |
Why?
|
Geographic Information Systems | 1 | 2016 | 39 | 0.130 |
Why?
|
Gastrointestinal Diseases | 1 | 2016 | 42 | 0.130 |
Why?
|
Hospitals, Psychiatric | 1 | 2015 | 14 | 0.130 |
Why?
|
Survival Rate | 2 | 2016 | 311 | 0.130 |
Why?
|
Earthquakes | 2 | 2013 | 7 | 0.130 |
Why?
|
Pregnancy Complications | 1 | 2016 | 126 | 0.130 |
Why?
|
Quality-Adjusted Life Years | 1 | 2015 | 44 | 0.130 |
Why?
|
Cross Infection | 1 | 2015 | 38 | 0.130 |
Why?
|
Interviews as Topic | 2 | 2014 | 381 | 0.130 |
Why?
|
Primary Health Care | 1 | 2017 | 294 | 0.120 |
Why?
|
Cross-Sectional Studies | 3 | 2014 | 2721 | 0.120 |
Why?
|
Shigella Vaccines | 1 | 2014 | 1 | 0.120 |
Why?
|
Guideline Adherence | 1 | 2015 | 84 | 0.120 |
Why?
|
Area Under Curve | 1 | 2014 | 88 | 0.120 |
Why?
|
Caliciviridae Infections | 2 | 2004 | 7 | 0.120 |
Why?
|
Infant Mortality | 1 | 2014 | 55 | 0.120 |
Why?
|
Antigens, Bacterial | 2 | 2006 | 132 | 0.120 |
Why?
|
Sanitary Engineering | 1 | 2013 | 2 | 0.120 |
Why?
|
Brachyura | 1 | 2014 | 15 | 0.120 |
Why?
|
Molecular Epidemiology | 2 | 2016 | 50 | 0.120 |
Why?
|
Biosurveillance | 1 | 2013 | 1 | 0.120 |
Why?
|
Drug Discovery | 1 | 2014 | 82 | 0.110 |
Why?
|
Epidemiologic Research Design | 1 | 2012 | 16 | 0.110 |
Why?
|
Multicenter Studies as Topic | 1 | 2012 | 41 | 0.110 |
Why?
|
Cyclonic Storms | 1 | 2014 | 64 | 0.110 |
Why?
|
Guyana | 1 | 2012 | 1 | 0.110 |
Why?
|
Floods | 1 | 2012 | 6 | 0.110 |
Why?
|
Pregnancy | 2 | 2016 | 1549 | 0.110 |
Why?
|
Vibrio mimicus | 1 | 2012 | 1 | 0.110 |
Why?
|
Vibrio Infections | 1 | 2012 | 4 | 0.110 |
Why?
|
Astacoidea | 1 | 2012 | 3 | 0.110 |
Why?
|
Enterobacteriaceae Infections | 1 | 2012 | 11 | 0.110 |
Why?
|
Mammea | 1 | 2012 | 1 | 0.110 |
Why?
|
Needs Assessment | 1 | 2013 | 170 | 0.100 |
Why?
|
Guatemala | 4 | 2019 | 17 | 0.100 |
Why?
|
Drug Resistance, Multiple | 2 | 2017 | 27 | 0.100 |
Why?
|
Survival Analysis | 1 | 2013 | 325 | 0.100 |
Why?
|
DNA Fingerprinting | 2 | 2008 | 18 | 0.100 |
Why?
|
Genotype | 2 | 2019 | 730 | 0.100 |
Why?
|
Hydrogen-Ion Concentration | 2 | 2011 | 364 | 0.100 |
Why?
|
Immunoglobulin M | 1 | 2012 | 82 | 0.100 |
Why?
|
Health Policy | 1 | 2013 | 165 | 0.100 |
Why?
|
Asia, Western | 3 | 2018 | 4 | 0.100 |
Why?
|
Environmental Monitoring | 3 | 2007 | 192 | 0.100 |
Why?
|
Guam | 1 | 2011 | 79 | 0.100 |
Why?
|
Practice Guidelines as Topic | 1 | 2011 | 191 | 0.090 |
Why?
|
Caregivers | 1 | 2013 | 182 | 0.090 |
Why?
|
Water | 2 | 2004 | 296 | 0.090 |
Why?
|
Fruit | 1 | 2012 | 173 | 0.090 |
Why?
|
Ohio | 3 | 2007 | 14 | 0.090 |
Why?
|
Housing | 2 | 2007 | 59 | 0.090 |
Why?
|
Immunohistochemistry | 1 | 2012 | 893 | 0.090 |
Why?
|
Enterotoxins | 2 | 2008 | 33 | 0.090 |
Why?
|
Reagent Kits, Diagnostic | 1 | 2009 | 12 | 0.090 |
Why?
|
Magnetic Resonance Imaging | 1 | 2012 | 481 | 0.090 |
Why?
|
Politics | 1 | 2009 | 40 | 0.090 |
Why?
|
Mali | 2 | 2023 | 3 | 0.090 |
Why?
|
History, 19th Century | 1 | 2009 | 24 | 0.080 |
Why?
|
Southeastern United States | 1 | 2008 | 49 | 0.080 |
Why?
|
History, 20th Century | 1 | 2009 | 117 | 0.080 |
Why?
|
Seafood | 1 | 2008 | 23 | 0.080 |
Why?
|
Salmonella paratyphi C | 1 | 2008 | 1 | 0.080 |
Why?
|
Salmonella paratyphi B | 1 | 2008 | 1 | 0.080 |
Why?
|
Violence | 1 | 2009 | 134 | 0.080 |
Why?
|
Cohort Studies | 3 | 2008 | 1492 | 0.080 |
Why?
|
Child Day Care Centers | 2 | 2009 | 11 | 0.080 |
Why?
|
Fluoroquinolones | 1 | 2008 | 7 | 0.080 |
Why?
|
Case Management | 1 | 2008 | 20 | 0.080 |
Why?
|
Drug Resistance | 1 | 2008 | 99 | 0.080 |
Why?
|
Relief Work | 1 | 2007 | 7 | 0.080 |
Why?
|
Water Pollutants | 1 | 2007 | 17 | 0.080 |
Why?
|
Louisiana | 1 | 2007 | 43 | 0.070 |
Why?
|
Respiratory Tract Diseases | 1 | 2007 | 23 | 0.070 |
Why?
|
Asia, Southeastern | 2 | 2018 | 8 | 0.070 |
Why?
|
Eating | 2 | 2014 | 166 | 0.070 |
Why?
|
Confidence Intervals | 3 | 2014 | 149 | 0.070 |
Why?
|
Humidity | 1 | 2006 | 11 | 0.070 |
Why?
|
Hot Temperature | 1 | 2007 | 128 | 0.070 |
Why?
|
Colony Count, Microbial | 1 | 2006 | 66 | 0.070 |
Why?
|
Trimethoprim Resistance | 1 | 2006 | 1 | 0.070 |
Why?
|
Ampicillin Resistance | 1 | 2006 | 3 | 0.070 |
Why?
|
Ampicillin | 1 | 2006 | 6 | 0.070 |
Why?
|
Illinois | 1 | 2005 | 9 | 0.070 |
Why?
|
Chronic Disease | 2 | 2006 | 484 | 0.070 |
Why?
|
Poliomyelitis | 2 | 2017 | 7 | 0.070 |
Why?
|
New York | 1 | 2005 | 71 | 0.070 |
Why?
|
Influenza in Birds | 2 | 2017 | 8 | 0.070 |
Why?
|
India | 2 | 2016 | 88 | 0.070 |
Why?
|
Birds | 2 | 2017 | 28 | 0.070 |
Why?
|
Mortality | 2 | 2019 | 145 | 0.060 |
Why?
|
Hospitals | 2 | 2018 | 86 | 0.060 |
Why?
|
Texas | 1 | 2006 | 324 | 0.060 |
Why?
|
Retrospective Studies | 3 | 2020 | 2026 | 0.060 |
Why?
|
Shigella boydii | 1 | 2004 | 1 | 0.060 |
Why?
|
Mass Vaccination | 2 | 2016 | 7 | 0.060 |
Why?
|
Naval Medicine | 1 | 2004 | 3 | 0.060 |
Why?
|
Ships | 1 | 2004 | 8 | 0.060 |
Why?
|
Vietnam | 1 | 2004 | 50 | 0.060 |
Why?
|
Beverages | 2 | 2017 | 68 | 0.060 |
Why?
|
Conservation of Natural Resources | 1 | 2004 | 35 | 0.060 |
Why?
|
Antibodies, Monoclonal | 1 | 2006 | 290 | 0.060 |
Why?
|
Hepatitis A | 1 | 2004 | 11 | 0.060 |
Why?
|
Kentucky | 1 | 2003 | 3 | 0.060 |
Why?
|
Indiana | 1 | 2003 | 15 | 0.060 |
Why?
|
Gambia | 1 | 2023 | 1 | 0.060 |
Why?
|
Petroselinum | 1 | 2003 | 4 | 0.060 |
Why?
|
Giardia | 1 | 2023 | 13 | 0.060 |
Why?
|
Public Health Practice | 2 | 2018 | 40 | 0.060 |
Why?
|
Gastrointestinal Hemorrhage | 1 | 2003 | 27 | 0.060 |
Why?
|
Cough | 1 | 2023 | 18 | 0.060 |
Why?
|
Helicobacter Infections | 1 | 2004 | 78 | 0.060 |
Why?
|
Chloramphenicol | 1 | 2022 | 5 | 0.050 |
Why?
|
Health Services Accessibility | 1 | 2007 | 560 | 0.050 |
Why?
|
Anthrax | 1 | 2002 | 19 | 0.050 |
Why?
|
Bioterrorism | 1 | 2002 | 20 | 0.050 |
Why?
|
International Cooperation | 1 | 2002 | 46 | 0.050 |
Why?
|
Infant Food | 1 | 2002 | 14 | 0.050 |
Why?
|
Reproducibility of Results | 1 | 2006 | 935 | 0.050 |
Why?
|
Safety | 1 | 2002 | 48 | 0.050 |
Why?
|
Demography | 1 | 2002 | 175 | 0.050 |
Why?
|
Reproduction | 1 | 2002 | 71 | 0.050 |
Why?
|
Salmonella typhimurium | 1 | 2021 | 40 | 0.050 |
Why?
|
Nevada | 2 | 2012 | 6 | 0.050 |
Why?
|
Microscopy, Electron, Scanning | 2 | 2009 | 142 | 0.040 |
Why?
|
Seroepidemiologic Studies | 2 | 2013 | 68 | 0.040 |
Why?
|
Community-Acquired Infections | 1 | 2019 | 22 | 0.040 |
Why?
|
Bangladesh | 2 | 2010 | 20 | 0.040 |
Why?
|
Cerebrovascular Disorders | 1 | 2019 | 37 | 0.040 |
Why?
|
Health Surveys | 2 | 2013 | 373 | 0.040 |
Why?
|
Swine | 1 | 2019 | 184 | 0.040 |
Why?
|
Chile | 1 | 2018 | 6 | 0.040 |
Why?
|
Risk Assessment | 2 | 2015 | 753 | 0.040 |
Why?
|
Phylogeny | 1 | 2021 | 644 | 0.040 |
Why?
|
Socioeconomic Factors | 1 | 2002 | 1067 | 0.040 |
Why?
|
Yellow Fever | 1 | 2017 | 4 | 0.040 |
Why?
|
California | 2 | 2012 | 476 | 0.040 |
Why?
|
Sheep, Domestic | 1 | 2017 | 7 | 0.040 |
Why?
|
Feeding Behavior | 1 | 2002 | 454 | 0.040 |
Why?
|
Animal Husbandry | 1 | 2017 | 18 | 0.040 |
Why?
|
Research Design | 1 | 2019 | 313 | 0.040 |
Why?
|
Zoonoses | 1 | 2017 | 17 | 0.040 |
Why?
|
Rodentia | 1 | 2017 | 43 | 0.040 |
Why?
|
Hemorrhagic Fever, Ebola | 1 | 2017 | 29 | 0.040 |
Why?
|
Advisory Committees | 1 | 2017 | 29 | 0.040 |
Why?
|
Pediatrics | 1 | 2018 | 68 | 0.040 |
Why?
|
Water Pollution | 1 | 2017 | 12 | 0.040 |
Why?
|
Data Collection | 1 | 2018 | 194 | 0.040 |
Why?
|
Follow-Up Studies | 1 | 2019 | 974 | 0.040 |
Why?
|
Melanesia | 1 | 2016 | 22 | 0.040 |
Why?
|
Gram-Negative Bacteria | 2 | 2009 | 22 | 0.040 |
Why?
|
Vomiting | 1 | 2016 | 14 | 0.040 |
Why?
|
Afghanistan | 1 | 2016 | 7 | 0.040 |
Why?
|
Antigens, Viral | 1 | 2016 | 43 | 0.040 |
Why?
|
Chickens | 1 | 2017 | 133 | 0.030 |
Why?
|
Parents | 1 | 2019 | 329 | 0.030 |
Why?
|
Data Mining | 1 | 2016 | 23 | 0.030 |
Why?
|
Environmental Exposure | 2 | 2012 | 216 | 0.030 |
Why?
|
Cryptosporidium parvum | 2 | 2007 | 3 | 0.030 |
Why?
|
Coronavirus Infections | 1 | 2017 | 68 | 0.030 |
Why?
|
Cambodia | 1 | 2015 | 3 | 0.030 |
Why?
|
Focus Groups | 1 | 2017 | 348 | 0.030 |
Why?
|
Diet | 1 | 2002 | 801 | 0.030 |
Why?
|
American Samoa | 1 | 2015 | 16 | 0.030 |
Why?
|
History, 21st Century | 1 | 2015 | 81 | 0.030 |
Why?
|
Health Resources | 1 | 2015 | 32 | 0.030 |
Why?
|
Morbidity | 1 | 2015 | 91 | 0.030 |
Why?
|
Pilot Projects | 1 | 2017 | 661 | 0.030 |
Why?
|
Fiji | 1 | 2014 | 1 | 0.030 |
Why?
|
Bacterial Typing Techniques | 1 | 2014 | 34 | 0.030 |
Why?
|
Pacific Islands | 1 | 2014 | 119 | 0.030 |
Why?
|
Sierra Leone | 1 | 2014 | 3 | 0.030 |
Why?
|
Disease Models, Animal | 1 | 2019 | 1371 | 0.030 |
Why?
|
Enterovirus A, Human | 1 | 2013 | 1 | 0.030 |
Why?
|
Markov Chains | 1 | 2013 | 35 | 0.030 |
Why?
|
Poliovirus | 1 | 2013 | 5 | 0.030 |
Why?
|
Enterovirus Infections | 1 | 2013 | 4 | 0.030 |
Why?
|
Influenza A Virus, H5N1 Subtype | 1 | 2013 | 5 | 0.030 |
Why?
|
Nonlinear Dynamics | 1 | 2013 | 33 | 0.030 |
Why?
|
Monte Carlo Method | 1 | 2013 | 57 | 0.030 |
Why?
|
Residence Characteristics | 1 | 2016 | 322 | 0.030 |
Why?
|
Inpatients | 1 | 2013 | 74 | 0.030 |
Why?
|
Tuberculosis | 1 | 2013 | 63 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2004 | 448 | 0.030 |
Why?
|
Washington | 1 | 2012 | 31 | 0.030 |
Why?
|
Blood Specimen Collection | 1 | 2012 | 12 | 0.030 |
Why?
|
Oregon | 1 | 2012 | 43 | 0.030 |
Why?
|
Contact Tracing | 1 | 2012 | 19 | 0.030 |
Why?
|
Emergencies | 1 | 2011 | 24 | 0.030 |
Why?
|
Middle East | 1 | 2011 | 18 | 0.030 |
Why?
|
Europe | 1 | 2011 | 101 | 0.020 |
Why?
|
DNA Topoisomerase IV | 1 | 2011 | 2 | 0.020 |
Why?
|
Databases, Factual | 1 | 2013 | 291 | 0.020 |
Why?
|
DNA Gyrase | 1 | 2011 | 7 | 0.020 |
Why?
|
Mental Disorders | 1 | 2015 | 309 | 0.020 |
Why?
|
Hospital Mortality | 1 | 2013 | 187 | 0.020 |
Why?
|
Malaria | 1 | 2012 | 78 | 0.020 |
Why?
|
Botswana | 1 | 2010 | 5 | 0.020 |
Why?
|
Infant Formula | 1 | 2010 | 15 | 0.020 |
Why?
|
Quality of Life | 1 | 2015 | 481 | 0.020 |
Why?
|
Gene Expression Regulation, Bacterial | 1 | 2011 | 149 | 0.020 |
Why?
|
Photoelectron Spectroscopy | 1 | 2009 | 5 | 0.020 |
Why?
|
Missouri | 1 | 2009 | 7 | 0.020 |
Why?
|
Poverty Areas | 1 | 2010 | 41 | 0.020 |
Why?
|
X-Ray Diffraction | 1 | 2009 | 57 | 0.020 |
Why?
|
Infection Control | 1 | 2009 | 14 | 0.020 |
Why?
|
Microscopy, Electron, Transmission | 1 | 2009 | 146 | 0.020 |
Why?
|
Health Care Costs | 1 | 2009 | 77 | 0.020 |
Why?
|
Breast Feeding | 1 | 2010 | 113 | 0.020 |
Why?
|
Streptococcus pneumoniae | 1 | 2008 | 30 | 0.020 |
Why?
|
Nanotechnology | 1 | 2009 | 153 | 0.020 |
Why?
|
Bacterial Toxins | 1 | 2008 | 44 | 0.020 |
Why?
|
Antimalarials | 1 | 2008 | 55 | 0.020 |
Why?
|
Flocculation | 1 | 2007 | 6 | 0.020 |
Why?
|
Disinfectants | 1 | 2007 | 7 | 0.020 |
Why?
|
Giardia lamblia | 1 | 2007 | 29 | 0.020 |
Why?
|
Malaria, Falciparum | 1 | 2008 | 90 | 0.020 |
Why?
|
Plasmodium falciparum | 1 | 2008 | 135 | 0.020 |
Why?
|
Campylobacter jejuni | 1 | 2007 | 22 | 0.020 |
Why?
|
Escherichia coli Proteins | 1 | 2008 | 126 | 0.020 |
Why?
|
Geography | 1 | 2007 | 96 | 0.020 |
Why?
|
China | 1 | 2007 | 196 | 0.020 |
Why?
|
Mutation | 1 | 2011 | 1095 | 0.020 |
Why?
|
Sex Distribution | 1 | 2007 | 215 | 0.020 |
Why?
|
O Antigens | 1 | 2006 | 5 | 0.020 |
Why?
|
Tennessee | 1 | 2006 | 70 | 0.020 |
Why?
|
Schools | 1 | 2007 | 260 | 0.020 |
Why?
|
Parasitic Diseases | 1 | 2004 | 6 | 0.020 |
Why?
|
Virus Diseases | 1 | 2004 | 22 | 0.020 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2005 | 221 | 0.020 |
Why?
|
Recreation | 1 | 2004 | 32 | 0.020 |
Why?
|
Hepatitis A virus | 1 | 2004 | 2 | 0.010 |
Why?
|
Viral Vaccines | 1 | 2004 | 29 | 0.010 |
Why?
|
Hydrotherapy | 1 | 2003 | 1 | 0.010 |
Why?
|
Acute Disease | 1 | 2004 | 147 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2008 | 1369 | 0.010 |
Why?
|
Micronesia | 1 | 2003 | 80 | 0.010 |
Why?
|
Diapers, Infant | 1 | 2003 | 1 | 0.010 |
Why?
|
HIV-1 | 1 | 2009 | 706 | 0.010 |
Why?
|
Nutritional Status | 1 | 2004 | 116 | 0.010 |
Why?
|
Minnesota | 1 | 2003 | 40 | 0.010 |
Why?
|
Antibodies, Protozoan | 1 | 2004 | 79 | 0.010 |
Why?
|
Culture Media | 1 | 2003 | 90 | 0.010 |
Why?
|
Bacterial Vaccines | 1 | 2004 | 125 | 0.010 |
Why?
|
Helicobacter pylori | 1 | 2004 | 109 | 0.010 |
Why?
|
Disease Notification | 1 | 2002 | 6 | 0.010 |
Why?
|
Canada | 1 | 2003 | 130 | 0.010 |
Why?
|
Bacillus anthracis | 1 | 2002 | 33 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2004 | 623 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2005 | 885 | 0.010 |
Why?
|
Phodopus | 1 | 2002 | 3 | 0.010 |
Why?
|
Survival | 1 | 2002 | 8 | 0.010 |
Why?
|
Litter Size | 1 | 2002 | 15 | 0.010 |
Why?
|
Dietary Carbohydrates | 1 | 2002 | 31 | 0.010 |
Why?
|
Dietary Proteins | 1 | 2002 | 32 | 0.010 |
Why?
|
Lactation | 1 | 2002 | 40 | 0.010 |
Why?
|
Occupational Exposure | 1 | 2002 | 79 | 0.010 |
Why?
|
Antibodies, Viral | 1 | 2004 | 262 | 0.010 |
Why?
|
Organ Size | 1 | 2002 | 157 | 0.010 |
Why?
|
Cricetinae | 1 | 2002 | 238 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 2005 | 420 | 0.010 |
Why?
|
Dietary Fats | 1 | 2002 | 119 | 0.010 |
Why?
|
Energy Intake | 1 | 2002 | 170 | 0.010 |
Why?
|
Body Composition | 1 | 2002 | 162 | 0.010 |
Why?
|
Kinetics | 1 | 2002 | 708 | 0.010 |
Why?
|
Adipose Tissue | 1 | 2002 | 177 | 0.010 |
Why?
|
Body Weight | 1 | 2002 | 434 | 0.010 |
Why?
|